CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
- EligibilityCriteria: Inclusion Criteria:  Age > 18 years and < 80 years. Diagnosis of invasive breast cancer [ stage I-III ] and planned anthracycline treatment within 60 days. Signed Informed Consent to participate in the study.  Exclusion Criteria:  Urinary tract infection with the need for treatment with an antibiotic 48 hours before the scheduled start of anthracycline treatment. Recognised heart failure or symptoms which, in the opinion of the investigator may be a symptom of undiagnosed heart failure. Left ventricular ejection fraction <50% at the time of the screening. Severe valvular heart disease. A history of clinically significant arrhythmia, including atrial fibrillation regardless of type (at discretion of the investigator). A history of stroke. Cardiomyopathy: congenital, post-inflammatory, toxic, infiltrative (e.g. amyloidosis, sarcoidosis, haemochromatosis), postnatal or hypertrophic. Pulmonary hypertension. Uncontrolled arterial pressure or systolic pressure <80 mmHg at screening at the discretion of the investigator. BMI>40 kg/m2. Diabetes type 1 or type 2. Pregnancy or breastfeeding. Taking another study drug or drugs from the group of SGLT2 inhibitors. eGFR <25 ml/min/1.73m2 according to CKD EPI Life expectancy <12 months or cancer disease stage IV according to the TNM classification. Any other condition which, in the opinion of the investigator, makes it impossible to fulfill the requirements for participation in this study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult